Accera has commenced a clinical trial evaluating the efficacy of 26 weeks daily administration of AC-1204 compared with placebo in patients with mild-to-moderate Alzheimer’s disease (AD).
AC-1204 is caprylic triglyceride designed to improve cognitive function in mild-to-moderate Alzheimer’s disease.
Accera president and CEO Holger Kunze said following an investment from Nestlé Health Science, the company is keen to produce additional data demonstrating the effectiveness of the product in Alzheimer’s disease patients.
"We believe we have a truly innovative approach that will meet the needs of patients in this overwhelmingly underserved market," Kunze said.
The randomised, double-blind, multi-centre study is expected to enrol more than 400 patients at around 60 clinical sites in the US.
Placebo-controlled, parallel-group trial will assess the effects of once daily dosing of AC-1204 for 26 weeks on cognition, pharmacokinetic measures, activities of daily living, resource utilisation and quality of life among subjects with mild-to-moderate AD.
The primary endpoint of the study includes the effect of AC-1204 on memory and cognition based on the Alzheimer’s disease Assessment Scale-cognitive subscale after 26 weeks, among both carriers and non-carriers of the epsilon 4 variant of the gene apolipoprotein E.
Earlier studies established proof-of-concept for the company’s approach of tackling the physiological characteristic of the brain’s inability to optimally metabolise glucose by providing an alternative energy source for brain cells.